In this article, we highlight key steps that were needed to integrate clinical pharmacy specialists at an academic ambulatory psychiatric and addiction treatment center that serves pediatric and adult populations. Academic stakeholders identified addition of pharmacy services as a strategic goal in an effort to maximize services offered by the center and increase patient access to care while aligning with the standards set out by the patient-centered medical home (PCMH) model.

We outline the role of clinical pharmacists in the care of adult patients in ambulatory psychiatry, illustrate opportunities to enhance patient care, point out possible challenges with implementation, and propose future initiatives to optimize the practitioner-pharmacist partnership.

Background: Role of ambulatory pharmacists in psychiatry

Clinical pharmacists’ role in the psychiatric ambulatory care setting generally is associated with positive outcomes. One study looking at a collaborative care model that utilized clinical pharmacist follow-up in managing major depressive disorder found that patients who received pharmacist intervention in the collaborative care model had, on average, a significantly higher adherence rate and patient satisfaction score than the “usual care” group.1 Within this study, patients in both groups experienced global clinical improvement with no significant difference; however, clinical pharmacists can play a vital role in ambulatory psychiatry, this model reveals

Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Clinical pharmacists

Clinical Point

Results so far indicate that pharmacists can have a positive impact on the care of ambulatory psychiatry patients.

Table 1

<table>
<thead>
<tr>
<th>System initiatives, opportunities for involving the pharmacist in psychiatry care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highlighting quality, including optimizing metabolic monitoring for patients treated with an atypical antipsychotic, as well as other best-practice issues</td>
</tr>
<tr>
<td>Optimizing transition of care to primary care providers and other specialists</td>
</tr>
<tr>
<td>Providing additional support and resources for psychiatry patients and for non-psychiatric providers</td>
</tr>
<tr>
<td>Fostering team-based care</td>
</tr>
<tr>
<td>Integrating care</td>
</tr>
<tr>
<td>Showcasing successful use of pharmacists in the patient-centered medical home model</td>
</tr>
<tr>
<td>Involving pharmacists in education of psychiatry residents</td>
</tr>
</tbody>
</table>

Note: This list is not exhaustive; it was thought that these initiatives in particular would most likely benefit from involvement of a pharmacist.

Pre-implementation

The need for pharmacy services. Various initiatives and existing practices within our health care system have underscored the need for a psychiatric pharmacist in the outpatient setting (Table 1).

A board-certified psychiatric pharmacist (BCPP) possesses specialized knowledge about treating patients affected by psychiatric illnesses. BCPPs work with prescribers and members of other disciplines, such as nurses and social workers, to optimize drug treatment by making pharmacotherapeutic recommendations and providing appropriate monitoring to enhance patient satisfaction and quality of life.3,4

Existing relationship with pharmacy.

Along with evidence to support the positive impact clinical pharmacists can have in caring for patients with mental illness in the outpatient setting, a strong existing relationship between the Department of Psychiatry and our adult inpatient psychiatric pharmacist helped make it possible to develop an ambulatory psychiatric pharmacist position.

Each day, the inpatient psychiatric pharmacist works closely with the attending psychiatrists and psychiatry residents to provide treatment recommendations and counseling services for patients on the unit. The psychiatry residents highly valued their experiences with the pharmacist in the inpatient setting and expressed disappointment that this collaborative relationship was no longer available after they transitioned into the ambulatory setting.

Further, by being involved in initiatives that were relevant to both inpatient and outpatient psychiatry, such as metabolic monitoring for patients taking atypical antipsychotics, the clinical pharmacist in inpatient psychiatry had the opportunity to interact with key stakeholders in both settings. As a result of these pre-existing collaborative relationships, many clinicians were eager to have pharmacists available as a resource for patient care in the outpatient setting.
Pharmacist perspective: Outreach to psychiatry leadership
Recognizing the incentives and opportunities inherent in our emerging health care system, pharmacists became integral members of the patient care team in the PCMH model. Thanks to this effort, we now have PCMH pharmacists at every primary care health center in our health system (14 sites), providing disease management programs and polypharmacy services.

PCMH pharmacists’ role in the primary care setting fueled interest from specialty services and created opportunities to extend our existing partnership in inpatient psychiatry. One such opportunity to demonstrate the expertise of a psychiatric pharmacist was fueled by the FDA’s citalopram dosing alert at a system-wide level. This warning emerged as a chance to showcase the skill set of psychiatric pharmacists and the pharmacists’ successes in our PCMH model. The partnership was extended to include the buy-in of ambulatory pharmacy leadership and key stakeholders in ambulatory psychiatry.

Initial meetings included ambulatory care site leadership in psychiatry to increase awareness and understanding of pharmacists’ potential role in direct patient care. Achieving site leadership support was critical to successful implementation of pharmacist services in psychiatry. We also obtained approval from the Chair of the Department of Psychiatry to elicit support from faculty group practice.

Psychiatry leadership perspective
As fiscal pressures intensify at academic health centers, it becomes increasingly important for resources to be used as efficiently and effectively as possible. As a greater percentage of mental health patients with more “straightforward,” less complex conditions are being managed by their primary care providers or non-prescribing psychotherapists, or both, the acuity and complexity of cases in patients who present to psychiatric clinics have intensified. This intensification of patient needs and clinical acuity is in heightened conflict with the ongoing demand for clinician productivity and efficiency.

Additionally, the need to provide care to a seemingly ever-growing number of moderately or severely ill patients during shorter, less frequent visits presents a daunting task for clinicians and clinical leaders. Collaborative care models appear to offer the best hope for managing the seemingly overwhelming demand for services.

In this model, the patient, who is the critical member of the team, is expected to become an “expert” on his or her illness and to partner with members of the multidisciplinary team; with this support, patients are encouraged to develop a broad range of self-management skills and strategies to manage their illness. We believe that clinical pharmacists can and should play a critical role, not only in delivering direct clinical services to patients but also in developing and devising the care models that will most effectively apply each team member’s unique set of knowledge, skills, and experience. Given the large percentage of our patients who have multiple medical comorbidities and who require complex medical and psychiatric medication regimens, the role of the pharmacist in reviewing, educating, and advising patients and other team members on these crucial pharmacy concerns will be paramount.

In light of these complex medication issues, pharmacists are uniquely positioned to serve as a liaison among the patient, the primary care provider, and other members of their treatment team. We anticipate that our ambulatory psychiatry pharmacists will greatly enhance the comfort and confidence of patients and their primary care providers during periods of care transition.

Potential roles for pharmacists in ambulatory psychiatry
One potential role for pharmacists in ambulatory psychiatry is to perform polypharmacy assessments of patients receiving complex medication regimens, prompted by physician referral. The poly-
Clinical pharmacists

Alongside its clinical model, our institution has developed a financial model to support the pharmacist’s role.

Clinical Point

Alongside its clinical model, our institution has developed a financial model to support the pharmacist’s role.

Table 2

<table>
<thead>
<tr>
<th>Key steps to take when starting an ambulatory pharmacy—psychiatry partnership</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Determine need or opportunities for pharmacist involvement in ambulatory psychiatry care</strong></td>
</tr>
<tr>
<td>• Align with current strategic goals and initiatives</td>
</tr>
<tr>
<td><strong>Approach key stakeholders from pharmacy and psychiatry</strong></td>
</tr>
<tr>
<td>• Promote buy-in, using the support of previously established relationships with psychiatry or other specialties</td>
</tr>
<tr>
<td><strong>Determine potential role(s) for pharmacists in ambulatory setting</strong></td>
</tr>
<tr>
<td>• Prepare specific, defined roles or sub-initiatives that will fit into the larger picture</td>
</tr>
<tr>
<td>• Record data that reflect progress (eg, increasing numbers of consults, patient visits, recommendations)</td>
</tr>
<tr>
<td>• Schedule a recurring meeting of ambulatory psychiatry leadership to assess outcomes and brainstorm solutions or new paths, if needed</td>
</tr>
<tr>
<td><strong>Promote new service to ambulatory psychiatry providers</strong></td>
</tr>
<tr>
<td>• Attend meetings of various groups to introduce the new service and explain the role a pharmacist can play in each practice</td>
</tr>
<tr>
<td>• If possible, partner with a particular clinic (eg, anxiety clinic) to form a new team; more face time with providers will likely increase the pharmacist’s involvement in patient care</td>
</tr>
<tr>
<td><strong>Assess reimbursement model for pharmacist visits by sounding out leadership</strong></td>
</tr>
<tr>
<td>• Track pharmacist billing; troubleshoot as needed</td>
</tr>
<tr>
<td><strong>Continue to meet with leadership to clarify existing roles</strong></td>
</tr>
<tr>
<td>• Continue to quantify progress</td>
</tr>
</tbody>
</table>

or adverse effects, drug-drug interactions, drug-nutrient interactions, and nonadherence. Pharmacists work to reduce medication costs if that is a concern of the patient, because nonadherence can result. A medication care plan is then developed in consultation with the primary care provider; here, the medication list is reconciled, the electronic medical record is updated, and actions to address any medication-related problems are prioritized.

Other services that might be offered include:

• group education classes, based on patient motivational interviewing strategies, to address therapeutic nonadherence and to improve understanding of their disease and treatment regimens
• medication safety and monitoring
• treatment intensification, as needed, following established protocols.

These are a few of the ways in which pharmacists can be relied on to expand and improve access to patient care services within ambulatory psychiatry. Key stakeholders anticipate development of newer ideas as the pharmacist’s role in ambulatory psychiatry is increasingly clarified.

Reimbursement model

In creating a role for pharmacy in ambulatory psychiatry, it was essential that the model be financially viable and appealing. Alongside its clinical model, our institution has developed a financial model to support the pharmacist’s role. The lump-sum payment to the health centers from Blue Cross Blue Shield of Michigan afforded the ambulatory care clinics an opportunity to invest in PCMH pharmacists. This funding, and the reimbursement based on T-code billing (face-to-face visits and phone consultation) for depression and other conditions requiring chronic care, provides ongoing support. From our experience, understanding physician reimbursement models and identifying relevant changes in health care reform are necessary to integrate new providers, including pharmacists, into a team-based care model.

pharmacy intake interview, performed to obtain an accurate medication list and to identify patients’ concerns about their medications, can be conducted in person or by telephone. Patients’ knowledge about medications and medication adherence are discussed, as are their perceptions of effectiveness and adverse effects.

After initial data gathering, pharmacists complete a review of the medications, identifying any problems associated with medication indication, efficacy, tolerance,
Implementation
Promoting pharmacy services. To foster anticipated collaboration with clinical pharmacists, the medical director of outpatient psychiatry disseminated an announcement to all providers regarding the investiture of clinical pharmacists to support patient care activities, education, and research. Clinicians were educated about the pharmacists’ potential roles and about guidelines and methods for referral. Use of our electronic health record system enabled us to establish a relatively simple referral process involving sharing electronic messages with our pharmacists.

Further, as part of the planned integration of clinical pharmacists in the ambulatory psychiatry setting, pharmacists met strategically with members of various disciplines, clinical programs, specialty clinic programs, and teams throughout the center. In addition to answering questions about the referral process, they emphasized the role of pharmacy and opportunities for collaboration.

Collaborating with others. Because the involvement of clinical pharmacists is unfamiliar to some practitioners in outpatient psychiatry, it is important to develop services without infringing on the roles other disciplines play. Indeed, a survey by Wheeler et al identified many concerns and potential boundaries among pharmacists, other providers, and patients. Concerns included confusion of practitioner roles and boundaries, a too-traditional perception of the pharmacist, and demonstration of competence.

Early on, we developed a structured forum to discuss ongoing challenges and address issues related to the rapidly changing clinical landscape. During these discussions we conveyed that adding pharmacists to psychiatric services would be collaborative in nature and intended to augment existing services. This communication was pivotal to maintain the psychiatrist’s role as the ultimate prescriber and authority in the care of their patients; however, the pharmacist’s expertise, when sought, would help spur clinical and academic discussion that will benefit the patient. These discussions are paramount to achieving a productive, team-based approach, to overcome challenges, and to identify opportunities of value to our providers and patients (Box).

How pharmacy positions itself as a clinical partner with physicians

Pharmacists are incredibly well-positioned as members of inter-professional teams to serve patients in the ambulatory setting and through care transitions. It’s no surprise that the fastest growing member segment of ASHP [the American Society of Health-System Pharmacists] is ambulatory care pharmacists, especially those who are seeing patients in clinics, physician office practices, accountable care organizations, medical homes, and ambulatory pharmacies in health systems…. ASHP has placed an increased emphasis on ambulatory care so that we now have a very comprehensive and growing set of resources to help ambulatory pharmacists care for their patients and chart a path to the future.”

Paul Abramowitz, PharmD, ScD (Hon), FASHP
Chief Executive Officer
American Society of Health-System Pharmacists

Source: Ambulatory care pharmacy practice: The future is now (see “Related Resources”)

Clinical Point
Using the electronic health record, we established a simple referral process, via electronic messages, with the pharmacists.

Work in progress
Implementing change in any clinical setting invariably creates challenges, and our endeavors to integrate clinical pharmacists into ambulatory psychiatry are no exception. We have identified several factors that we believe will optimize successful collaboration between pharmacy and ambulatory psychiatry (Table 2). Our primary challenge has been changing clinician behavior. Clinical practitioners can become too comfortable, wedded to their routines, and often are understandably resistant to change. Additionally, clinical systems often are inadvertently designed to obstruct change in ways that are not readily apparent. Efforts must be focused on behaviors and practices the clinical culture should encourage.
Regarding specific initiatives, clinical pharmacists have successfully identified patients on higher than recommended dosages of citalopram; they are working alongside prescribers to recommend ways to minimize the risk of heart rhythm abnormalities in these patients. Numerous prescribers have sought clinical pharmacists’ input to manage pharmacotherapy in their patients and to respond to patients’ questions on drug information.

The prospect of access to clinical pharmacist expertise in the outpatient setting was heralded with excitement, but the flow of referrals and consultations has been uneven. However simple the path for referral is, clinicians’ use of the system has been inconsistent—perhaps because of referrals’ passive, clinician-dependent nature. Educational outreach efforts often prompt a brief spike in referrals, only to be followed over time by a slow, steady drop-off. More active strategies will be needed, such as embedding the pharmacists as regular, active, visible members of the various clinical teams, and implementing a system in which patient record reviews are assigned to the pharmacists according to agreed-upon clusters of clinical criteria.

One of these tactics has, in the short term, showed success. Embedded in one of our newer clinics, which were designed to bridge primary and psychiatric care, clinical pharmacists are helping manage medically complicated patients. They assist with medication selection in light of drug interactions and medical comorbidities, conduct detailed medication histories, schedule follow-up visits to assess medication adherence and tolerability, and counsel patients experiencing insurance changes that make their medications less affordable. Integrating pharmacists in the new clinics has resulted in a steady flow of patient referrals and collaborative care work.

Clinical pharmacists are brainstorming with outpatient psychiatry leadership to build on these early successes. Ongoing communication and enhanced collaboration are essential, and can only improve the lives of our psychiatric patients.

**For the future**

Our partnership in ambulatory psychiatry was timed to occur during implementation of our health system’s new electronic health record initiative. Clinical pharmacists can play a key role in demonstrating use of the system to provide consistently accurate drug information to patients and to monitor patients receiving specific medications.

Development of ambulatory patient medication education groups, which

**Bottom Line**

Because psychiatric outpatients present with challenging medical comorbidities and increasingly complex medication regimens, specialized clinical pharmacists can enrich the management team by offering essential monitoring and polypharmacy services, patient education and counseling, and cross-discipline training. At one academic treatment center, psychiatric and non-psychiatric practitioners are gradually buying in to these promising collaborative efforts.
has proved useful on the inpatient side, is another endeavor in the works. Integrating the clinical pharmacist with psychiatrists, psychologists, nurse practitioners, social workers, and trainees on specific teams devoted to depression, bipolar disorder, anxiety, perinatal mental health, and personality disorders also might prove to be a wide-ranging and promising strategy.

Enhancing the education and training experiences of residents, fellows, medical students, pharmacy students, and allied health professional learners present in our clinics is another exciting prospect. This cross-disciplinary training will yield a new generation of providers who will be more comfortable collaborating with colleagues from other disciplines, all intent on providing high-quality, efficient care. We hope that, as these initiatives take root, we will recognize many opportunities to disseminate our collaborative efforts in scholarly venues, documenting and sharing the positive impact of our partnership.

References

Katie, age 6, is described by her teacher as inattentive, talking “a mile a minute” and interrupting others, and running from one classroom activity to another. Her parents note that Katie often is giddy, speaks loudly, and throws tantrums when asked to do chores. How would you proceed?

- Evaluate her symptoms using the Young Mania Rating Scale
- Create a pediatric bipolar disorder nomogram and ask her parents to fill out the Vanderbilt ADHD Diagnostic Parent Rating Scale
- Prescribe methylphenidate and follow up in 1 month
- Consult DSM-5 for symptoms of bipolar disorder and ADHD, obtain a family history, and make a clinical diagnosis

See "An irritable, inattentive, and disruptive child: Is it ADHD or bipolar disorder?" pages 30-44

Visit CurrentPsychiatry.com to answer the Instant Poll and see how your colleagues responded. Click on “Have more to say?” to comment.

MAY POLL RESULTS

Mr. R, age 40, has a history of epileptic seizures. He takes antiepileptic medication and has not had a seizure in months, yet says he despairs that he will have another seizure—and that this has led to poor sleep habits and suicidal ideation. Which treatment option would you choose for Mr. R?

- 4% Stop the antiepileptic medication and cautiously monitor Mr. R for remission of depression— and for recurrence of seizures
- 37% Prescribe a combination of an antiepileptic and antidepressant
- 57% Add a course of cognitive-behavioral therapy to the antiepileptic regimen
- 2% Consider electroconvulsive therapy or vagus nerve stimulation

Data obtained via CurrentPsychiatry.com, May 2014